Weekly FDA Drug Pipeline Calendar (April 17 - April 21)
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
$Merck & Co(MRK.US$ said Sunday it has agreed to acquire all of the outstanding shares of $Prometheus Biosciences(RXDX.US$ for $200 per share in cash, for a total equity value of about $10.8 billion.
Under the terms of the deal, Merck will acquire Prometheus through a subsidiary. The deal is expected to close in Q3, subject to approval from Prometheus shareholders.
Prometheus is developing PRA023 for the potential treatment of immune-mediated diseases, including ulcerative colitis, Crohn's disease and other autoimmune conditions.
EVENTS TO WATCH
Source: BioPharmCatalyst, Benzinga
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
We are the content provider of Moomoo Courses.
910Followers
8Following
1459Visitors
Follow